Showing 19,841 - 19,860 results of 66,188 for search '(( e fold decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 0.96s Refine Results
  1. 19841
  2. 19842

    Table 5_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…</p>Results<p>Patients treated before 12 months of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). …”
  3. 19843
  4. 19844
  5. 19845

    Data Sheet 1_SARS-CoV-2 post-acute sequelae linked to inflammation via extracellular vesicles.pdf by Sara Bachiller (15231716)

    Published 2025
    “…Background<p>Despite the efficacy of SARS-CoV-2 vaccines in reducing mortality and severe cases of COVID-19, a proportion of survivors experience long-term symptoms, known as post-acute sequelae of SARS-CoV-2 infection (PASC). …”
  6. 19846
  7. 19847
  8. 19848
  9. 19849
  10. 19850
  11. 19851
  12. 19852
  13. 19853

    Inactivation of the <i>Caenorhabditis elegans</i> RNF-5 E3 ligase promotes IRE-1-independent ER functions by Orit Adir (718546)

    Published 2022
    “…We demonstrate that downregulation of RNF-5 decreased sensitivity to tunicamycin both in wild type and in an <i>ire-1</i> mutant. …”
  14. 19854

    Additional file 5 of Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors by Yingjie Zhu (240610)

    Published 2024
    “…Additional file 5: Table S4. Transcriptional decreased genes in the enriched loci with deletions. …”
  15. 19855
  16. 19856

    Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability by Richard T. Eastman (6051881)

    Published 2025
    “…The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. …”
  17. 19857

    Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability by Richard T. Eastman (6051881)

    Published 2025
    “…The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. …”
  18. 19858

    Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability by Richard T. Eastman (6051881)

    Published 2025
    “…The antiparasitic drug ivermectin was proposed as a repurposed drug for the treatment of SARS-CoV-2 infection based on in vitro studies, but proved ineffective in high-quality clinical trials. …”
  19. 19859

    DataSheet_1_TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation.docx by Yong Shi (306872)

    Published 2021
    “…G-protein coupled bile acid receptor 1 (TGR5) is a cell surface receptor that is involved in multiple metabolic pathways. …”
  20. 19860

    Post-losartan treatment prevented SARS-CoV-2 Spike protein-induced vascular rarefaction but not pre-losartan treatment. by Mackenzi Meier (19251139)

    Published 2024
    “…Pre-Losartan treatment showed decreased vascular density. Only post-losartan treatment showed a protective effect and restored vascular density compared to control. …”